Revalesio Attempts to Help One of Their Own With Potential ALS Therapy

Scientist Tony Wood was instrumental in developing oxygen-enriched saline to speed the growth of hydroponic plants in developing countries. In 2007, researchers at Stanford University showed that the oxygen-enriched saline had anti-inflammatory properties, and might also benefit people with neuro-inflammatory diseases, including multiple sclerosis (MS), Parkinson’s, and Alzheimer’s. Currently, plans are underway for a phase II clinical trial of Revalesio Corp.’s oxygen-enriched saline (RNS60) for the treatment of MS. In a strange turn of events, Wood was recently diagnosed with a rapidly-progressing form of ALS and requested to treat himself with the oxygen-enriched saline that he developed. The FDA approved Wood’s request, and now he is in a single-patient trial at the UT Southwestern Medical Center testing RNS60 for the treatment of ALS.

Scientist Tony Wood was instrumental in developing oxygen-enriched saline to speed the growth of hydroponic plants in developing countries. In 2007, researchers at Stanford University showed that the oxygen-enriched saline had anti-inflammatory properties, and might also benefit people with neuro-inflammatory diseases, including multiple sclerosis (MS), Parkinson’s, and Alzheimer’s. Currently, plans are underway for a phase II clinical trial of Revalesio Corp.’s oxygen-enriched saline (RNS60) for the treatment of MS. In a strange turn of events, Wood was recently diagnosed with a rapidly-progressing form of ALS and requested to treat himself with the oxygen-enriched saline that he developed. The FDA approved Wood’s request, and now he is in a single-patient trial at the UT Southwestern Medical Center testing RNS60 for the treatment of ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail